ARTICLE | Clinical News
ISIS 2302: Began Phase IIa study
December 13, 1999 8:00 AM UTC
Isis Pharmaceuticals Inc. (ISIP) Carlsbad, Calif. Product: ISIS 2302 Business: Autoimmune/Inflammation Therapeutic category: Antisense Target: ICAM-1 Description: Antisense inhibitor of intercellul...